SLRX
Salarius Pharmaceuticals Inc
Halal Rating :
Last Price
$2.67
Last updated:
Market Cap
-
7D Change
-27.25%
1 Year Change
389.91%
Company Overview
Industries
Exchange
Next Earnings Date
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company's lead drug candidate, seclidemstat, is being developed for the treatment of Ewing sarcoma, a rare pediatric bone cancer, and other cancers. The company is currently in the research and development phase and has not yet commercialized any products.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Salarius Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.